Syros Pharmaceuticals, Inc. Contracts & Agreements
62 Contracts & Agreements
- Business Finance (26 contracts)
- Business Operations (3)
- Human Resources (13)
- Intellectual Property (2)
- Mergers & Acquisitions (1)
- Real Estate (2)
- Uncategorized (15)
- Separation Agreement, dated October 16, 2023, by and between the Registrant and Eric. R. Olson, Ph.D (Filed With SEC on March 27, 2024)
- Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on March 27, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on December 19, 2023)
- Underwriting Agreement, dated December 18, 2023, by and among Syros Pharmaceuticals, Inc., Cowen and Company, LLC and Piper Sandler & Co (Filed With SEC on December 19, 2023)
- Amended and Restated Offer Letter, dated September 28, 2023, by and between the Registrant and Conley Chee (Filed With SEC on November 14, 2023)
- Retirement and Transition Agreement, dated September 28, 2023, by and between the Registrant and Nancy Simonian, M.D (Filed With SEC on November 14, 2023)
- Second Amendment to Loan and Security Agreement, dated August 31, 2022, by and among the Registrant and Oxford Finance LLC, as collateral agent and lender (Filed With SEC on November 14, 2022)
- Form of Stock Option Agreement Under 2022 Equity Incentive Plan (Filed With SEC on November 14, 2022)
- Form of Restricted Stock Unit Agreement Under 2022 Equity Incentive Plan (Filed With SEC on November 14, 2022)
- Form of Restricted Stock Agreement Under 2022 Equity Incentive Plan (Filed With SEC on November 14, 2022)
- Syros Pharmaceuticals, Inc. Amended and Restated Director Compensation Policy (Filed With SEC on November 14, 2022)
- Form of Syros Pharmaceuticals, Inc. 2022 Equity Incentive Plan (Filed With SEC on July 18, 2022)
- Form of Warrant to Purchase Common Stock or Pre-Funded Warrants (Filed With SEC on July 5, 2022)
- Amendment to Loan and Security Agreement, dated July 3, 2022, by and among Syros Pharmaceuticals, Inc. and Oxford Finance LLC, as collateral agent and lender (Filed With SEC on July 5, 2022)
- Registration Rights Agreement, dated July 3, 2022, by and among Syros Pharmaceuticals, Inc., 667, L.P. and Baker Brothers Life Sciences, L.P (Filed With SEC on July 5, 2022)
- Registration Rights Agreement, dated July 3, 2022, by and among Syros Pharmaceuticals, Inc. and the persons party thereto (Filed With SEC on July 5, 2022)
- Securities Purchase Agreement, dated July 3, 2022, by and among Syros Pharmaceuticals, Inc. and the persons party thereto (Filed With SEC on July 5, 2022)
- Form of Lock-up Agreement (Filed With SEC on July 5, 2022)
- Forms of Tyme Support Agreement (Filed With SEC on July 5, 2022)
- Form of Syros Support Agreement (Filed With SEC on July 5, 2022)
- Form of Pre-Funded Warrant (Filed With SEC on July 5, 2022)
- Agreement and Plan of Merger, dated July 3, 2022, by and among Syros Pharmaceuticals, Inc., Tack Acquisition Corp. and Tyme Technologies, Inc (Filed With SEC on July 5, 2022)
- Master Collaboration Agreement dated March 7, 2022 between Syros Pharmaceuticals, Inc. and QIAGEN Manchester Limited (Filed With SEC on May 16, 2022)
- Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on March 15, 2022)
- 2022 Inducement Stock Incentive Plan (Filed With SEC on March 15, 2022)
- Form of Nonstatutory Stock Option Agreement under 2022 Inducement Stock Incentive Pla (Filed With SEC on March 15, 2022)
- Form of Restricted Stock Unit Agreement under 2022 Inducement Stock Incentive Plan (Filed With SEC on March 15, 2022)
- Offer Letter, effective September 27, 2021, between Syros Pharmaceuticals, Inc. and Conley Chee (Filed With SEC on November 5, 2021)
- Form of Nonstatutory Stock Option Agreement for Inducement Awards (Filed With SEC on October 13, 2021)
- Offer Letter, effective October 12, 2021, between Syros Pharmaceuticals, Inc. and Jason Haas (Filed With SEC on October 13, 2021)
- Amendment No. 1 to Amended and Restated Cancer License Agreement, dated January 8, 2021, by and between the Registrant and TMRC Co., Ltd (Filed With SEC on May 6, 2021)
- Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on March 4, 2021)
- Underwriting Agreement, dated January 19, 2021, by and among Syros Pharmaceuticals, Inc., Cowen and Company, LLC and Piper Sandler & Co., as representatives of the several... (Filed With SEC on January 20, 2021)
- Registration Rights Agreement, dated December 4, 2020, by and among Syros Pharmaceuticals, Inc. and the persons party thereto (Filed With SEC on December 7, 2020)
- Securities Purchase Agreement, dated December 4, 2020, by and among Syros Pharmaceuticals, Inc. and the persons party thereto (Filed With SEC on December 7, 2020)
- Form of Pre-Funded Warrant (Filed With SEC on December 7, 2020)
- Form of Warrant to Purchase Common Stock or Pre-Funded Warrants (Filed With SEC on December 7, 2020)
- Asset Purchase Agreement, dated as of December 4, 2020, by and between Syros Pharmaceuticals, Inc. and Orsenix, LLC (Filed With SEC on December 7, 2020)
- Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on March 5, 2020)
- Offer Letter dated April 24, 2013 by and between the Registrant and Eric R. Olson, Ph.D (Filed With SEC on March 5, 2020)
- Letter Agreement dated November 18, 2019 by and between the Registrant and Incyte Corporation (Filed With SEC on March 5, 2020)
- License and Collaboration Agreement dated December 17, 2019 by and between the Registrant and Global Blood Therapeutics, Inc (Filed With SEC on March 5, 2020)
- Loan and Security Agreement, dated February 12, 2020, by and among Syros Pharmaceuticals, Inc. and Oxford Finance LLC, as collateral agent and lender (Filed With SEC on February 13, 2020)
- Consulting Agreement dated August 8, 2012 between the Registrant and Richard A. Young, Ph.D., as amended (Filed With SEC on November 12, 2019)
- Lease Termination Agreement dated as of November 1, 2019 between Syros Pharmaceuticals, Inc. and 620 Memorial Leasehold LLC (Filed With SEC on November 4, 2019)
- Underwriting Agreement relating to the Common Offering, dated April 5, 2019, by and among Syros Pharmaceuticals, Inc., Cowen and Company, LLC and Piper Jaffray & Co., as... (Filed With SEC on April 8, 2019)
- Underwriting Agreement relating to the Preferred Offering, dated April 5, 2019, by and among Syros Pharmaceuticals, Inc., Cowen and Company, LLC and Piper Jaffray & Co., as... (Filed With SEC on April 8, 2019)
- Form of Class A Warrant (Filed With SEC on April 8, 2019)
- Form of Series A Convertible Preferred Stock Certificate (Filed With SEC on April 8, 2019)
- Form of Restricted Stock Unit Agreement under 2016 Stock Incentive Plan (Filed With SEC on March 7, 2019)
- Amended and Restated Cancer License Agreement dated April 28, 2016 by and between the Registrant and TMRC Co., Ltd (Filed With SEC on March 7, 2019)
- Lease dated January 8, 2019 between the Company and DIV 35 CPD, LLC (Filed With SEC on January 11, 2019)
- Offer Letter effective March 12, 2018 between Syros Pharmaceuticals, Inc. and Joseph J. Ferra, Jr (Filed With SEC on March 12, 2018)
- Target Discovery, Research Collaboration and Option Agreement dated January 8, 2018 by and between the Registrant and Incyte Corporation (Filed With SEC on March 12, 2018)
- Offer Letter dated November 6, 2017 by and between the Registrant and Jeremy Springhorn, Ph.D (Filed With SEC on March 12, 2018)
- Stock Purchase Agreement dated January 8, 2018 by and between the Registrant and Incyte Corporation, as amended (Filed With SEC on March 12, 2018)
- Underwriting Agreement, dated January 30, 2018, by and among Syros Pharmaceuticals, Inc., J.P. Morgan Securities LLC, Cowen and Company, LLC and Piper Jaffray & Co., as... (Filed With SEC on January 31, 2018)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on April 21, 2017)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on April 21, 2017)
- CONSULTING AGREEMENT (Filed With SEC on March 20, 2017)
- - 1 - (Filed With SEC on March 20, 2017)
- [Number of Shares] SYROS PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on June 20, 2016)